RedHill Biopharma (RDHL) Tops Q3 EPS Views; Announces RIZAPORT Marketing Approval in Germany
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to RedHill Biopharma (RDHL) Tops Q3 EPS Views; Announces RIZAPORT Marketing Approval in Germany
November 9, 2015 7:00 AM EST
Key Highlights Include:
A strong cash position of approximately $64 million at the end of the third quarter of 2015 following the Company's July 2015 public offering in the U.S. with gross proceeds of $44.5 million
Recent key milestones include the first European marketing approval of RIZAPORT announced today, positive top-line results from the Phase I study with YELIVA (ABC294640) in advanced solid tumors and the initiation of a Phase I/II study with YELIVA for diffuse large B-cell lymphoma
RedHill continues to advance the...
More
November 9, 2015 6:00 AM EST
The German Federal Institute for Drugs and Medical Devices (BfArM) has granted national marketing approval for RIZAPORT (RHB-103) for the treatment of acute migraines under the European Decentralized Procedure (DCP)
RedHill and IntelGenx continue their close cooperation in order to obtain approvals in additional European countries and in the U.S., where a New Drug Application (NDA) was submitted and a Complete Response Letter was received
RedHill and IntelGenx continue to advance their activities to secure commercialization partners in Europe, the U.S. and additional territories... More
